Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. - Wikidata - awgldk - TriplyDB

Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.

Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.

http://www.wikidata.org/entity/Q30544056

about

Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death Cognitive profile of LRRK2-related Parkinson's disease An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.The neurobiological basis of cognitive impairment in Parkinson's disease.Blood-based biomarkers for Parkinson's disease APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.A novel common variant in DCST2 is associated with length in early life and height in adulthood What can biomarkers tell us about cognition in Parkinson's disease?The significance of GBA for Parkinson's disease.Genetic convergence of Parkinson's disease and lysosomal storage disorders.Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease.Gender differences in Parkinson's disease: A clinical perspective.Cognitive decline in Parkinson disease.Biomarkers in Prodromal Parkinson Disease: a Qualitative Review.How close are we to individualized medicine for Parkinson's disease?Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analyses.Glucocerebrosidase Mutations in Parkinson Disease.Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.Identification of β-glucosidase 1 as a biomarker and its high expression in hepatocellular carcinoma is associated with resistance to chemotherapy drugs.Multisystem Lewy body disease and the other parkinsonian disorders.Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.Impact of Parkinson's disease risk loci on age at onset.Selective Patterns of Cognitive Impairment in Spinocerebellar Ataxia Type 6 and Idiopathic Late-Onset Cerebellar Ataxia.APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.GBA-Associated Parkinson's Disease: Progression in a Deep Brain Stimulation Cohort.Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease.Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease.Increased levels of MIP-1α in CSF and serum of ALS.Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease

P2860

Q27300869-1CE7D09E-1FF7-4EDF-AF59-D00B4A315F5B Q27333093-D2A73931-4174-4826-A123-049B8EA02B90 Q28552902-BAF6D5A8-BDF1-4E11-9933-C274A5E25120 Q30700188-9B93210B-ABF5-4A8F-ABF5-C7C3BE0CABC0 Q33724698-0CC48446-3152-449B-9F96-AA47FDB5DAB3 Q33804255-9BDA1285-E1ED-48E1-8FE0-307157EF025A Q34490496-E8572BC9-9E09-4B29-B80C-D6BC972C2C91 Q35661744-6588CE82-4E7B-44E4-B228-9CD96FC5D1BB Q38206497-88B9C3F3-3744-4E9D-AEF7-074791E45620 Q38217376-F5594C8F-D677-4966-B5AB-DDC4B2F8F48E Q38237560-6D670EF1-9B22-49BB-B588-27F273E59C12 Q38376569-FE964AA0-63C4-4029-869B-9FB5A034AA2E Q38697373-B557A9A1-7D19-47D5-84F9-D23FB8D6A3EE Q38751099-0909E678-36F9-4BFF-85BC-1F963FE84719 Q38788917-A97152D4-2521-4C73-A521-AD92F29A0AE7 Q38814888-D82A762E-2D39-4D32-B3FA-0B7488ED4F54 Q39332667-279D979A-6CD8-41DA-9F6E-518DC81E9DC5 Q39362339-A1DAE691-0072-4C99-AD3A-4833B2648515 Q39967268-4D073928-3412-4DA5-90CA-C9428DEC52CE Q40019761-FE982777-220A-40C1-9493-4D94FF6F1642 Q40260539-79532F0D-C8CC-4EC9-A897-5C3B3BFA96C2 Q40603461-AD1488BD-B64B-4EDE-95E8-2AB8E29105D4 Q43673984-B965B121-3E0C-4D32-9522-B50EAFC994C4 Q46158439-F644E276-8B25-494D-BF95-EB76A0F0136A Q47571451-91B87E22-2CDD-4A58-B0EF-37829D640D1A Q48166081-7B5655DD-AF5F-48F1-9E4E-3C108E4D4BC7 Q48350333-784D3F95-5BB1-4A54-AD94-1C0E2B9A82CF Q50506611-33A5DCFE-04DD-4389-B3CC-8CE2E85E489E Q53325097-0A17C29F-B1C3-4B5F-8DBB-E0DD85843088 Q54982491-934D8BB6-22A8-4A9A-BD23-16E272657716 Q58603525-798F3BF2-3ACB-4B3C-B325-5AD8BDE82F84

P2860

Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.

http://www.wikidata.org/entity/Q30544056

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Clinical and biochemical diffe ...... with vs without GBA mutations.

@ast

Clinical and biochemical diffe ...... with vs without GBA mutations.

@en

type

label

Clinical and biochemical diffe ...... with vs without GBA mutations.

@ast

Clinical and biochemical diffe ...... with vs without GBA mutations.

@en

prefLabel

Clinical and biochemical diffe ...... with vs without GBA mutations.

@ast

Clinical and biochemical diffe ...... with vs without GBA mutations.

@en

P1433

Q30544056-52F02CD7-F94A-4625-96F2-796644704425

P1476

Q30544056-6166C878-8401-42AE-866D-F266A0ADA238

P2093

Q30544056-1DEC1194-1C57-4F35-8E0C-418771F26E1D

Q30544056-5D28D578-5698-4A52-961B-DD39FC34E093

Q30544056-7735C753-AE40-4343-8837-7CBC1AA16824

Q30544056-81240C7A-6E05-49FC-AE13-FB8E1B49F8FE

Q30544056-8EB2479D-07DF-48E7-A50A-31B9D45C051B

Q30544056-8ED40B6D-08D8-4BF6-A7E1-E6D7527D548D

Q30544056-A6C8917E-A11E-4883-A2E0-7604D876F8DE

Q30544056-ADD75AB1-2D11-41FA-95C4-6AC09D2446ED

Q30544056-E83DDD81-6363-4A79-BCC7-925C8F78A9A5

Q30544056-F0D9B53C-672A-4B14-AEBC-94393DC65FD2

P2860

Q30544056-04E643DE-BB40-4648-9BC5-8B10BC0F20C7

Q30544056-07111E49-1C91-4BCA-A259-C0BBF49AD51A

Q30544056-0854D333-C8E2-4545-8D44-091CFE512176

Q30544056-2E223C0C-14D8-46EC-BBF1-FB8B265D065E

Q30544056-33A0771B-4A7C-4CAB-A5F7-8EFDECC68BE3

Q30544056-3A5B1968-2178-4CF9-89E5-593F22711882

Q30544056-46F0BE3E-5FBC-45D2-A4C5-A42BBC687302

Q30544056-4BA9CF10-6C46-4FDF-A9EA-9153FB7E4350

Q30544056-55D81274-E49D-4D77-A4FB-5348C018232C

Q30544056-684BAEAF-B750-458B-B625-CBDE24F81729

P304

Q30544056-E9430E9D-2D76-48C2-A93E-40D584721AD5

P31

Q30544056-F7054ED0-6CAE-4895-B258-C61553514F42

P356

Q30544056-C7C55907-76C4-4C91-B2B6-FE8E9E839ACF

P407

Q30544056-8F2F023B-629A-4BE1-A9EE-721C707B051E

P433

Q30544056-8D32FAA6-94ED-446F-B6CD-1F5F730A20C4

P478

Q30544056-F05A076B-3910-4D0D-A4A3-3520D13BA65C

P50

Q30544056-37EADFAD-59F5-4946-AEF8-64C0F4EDB6C5

Q30544056-487DEB4D-41E8-4C25-A023-C244B47E1BF4

Q30544056-7D52AC58-8FBA-4503-ADC4-E82DA3E5607A

P577

Q30544056-F8854709-D822-4DA4-8502-1FD668E93E31

P698

Q30544056-BEF58F85-AF23-45B1-88FE-239CF7C48B99

P921

Q30544056-AB6A8711-492D-40D5-AE6E-9D8BADE3B6BC

P932

Q30544056-DA79461B-55C2-4C35-AA88-57BCB0F40991

P356

JAMANEUROL.2013.1274

P1433

P1476

Clinical and biochemical diffe ...... with vs without GBA mutations

@en

P2093

Alice Chen-Plotkin

http://www.w3.org/2001/XMLSchema#string

Amy Colcher

http://www.w3.org/2001/XMLSchema#string

Andrew D Siderowf

http://www.w3.org/2001/XMLSchema#string

Dora Yearout

http://www.w3.org/2001/XMLSchema#string

Emily Ashbridge

http://www.w3.org/2001/XMLSchema#string

Howard I Hurtig

http://www.w3.org/2001/XMLSchema#string

James Minger

http://www.w3.org/2001/XMLSchema#string

John Q Trojanowski

http://www.w3.org/2001/XMLSchema#string

Judy Qiang

http://www.w3.org/2001/XMLSchema#string

Stacy Horn

http://www.w3.org/2001/XMLSchema#string

P2860

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease

Parkinsonism: onset, progression and mortality

Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology.

Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.

Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders.

P304

852-858

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMANEUROL.2013.1274

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Cyrus P Zabetian

James B Leverenz

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23699752

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3762458

http://www.w3.org/2001/XMLSchema#string